| 浅析伊立替康联合FP方案治疗晚期食管癌疗效 |
|
|
|
up and control group, and 37 cases received chemotherapy of PIF regimen.36 cases received chemotherapy of PF regimen.Each patient received at least 2 cyclesof chemotherapy. Results The efficacy and adverse events were evaluated in all patients. The overall response ratewas 59.46% in the PIF group and 46.67% in the PF group, the difference between the two groups did not reach statistical significance(P>0.05). The median time to progression(TTP）was 5.9 months in the PIF group and 4.4 months in the PF group.Themedian survival time(MST)was 12.2 months in the IP group and 9.3 months in the PF group.The main adverse events included elosuppression, nausea, vomiting and diarrhea.A lone diarrheawith statistically significant difference detected(P<0.05). Conclusion For advanced esophageal cancerpatients, PIF treatment achieves better therapeutic effects than PF treatment. it is toxicity is tolerable, It is valuable for clinical practicing.
【Key words】 Irinotecan;Advanced esophageal 上一页 [1] [2] [3] [4] [5] [6] 下一页 |
|
|
| |
|
上一个论文： 浅析杭锦后旗浅层地下水砷赋存形态
下一个论文： 浅谈分泌性中耳炎致儿童骨导听阈下降21例 |
|
用户登录 
新用户注册 